Kangstem Biotech Co (XKRX:217730) ROCE % : -33.17% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Kangstem Biotech Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kangstem Biotech Co's annualized ROCE % for the quarter that ended in Dec. 2024 was -33.17%.

Kangstem Biotech Co ROCE % Historical Data

The historical data trend for Kangstem Biotech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kangstem Biotech Co ROCE % Chart

Kangstem Biotech Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-23.50

-27.89

-27.49

-37.72

-12.64

Kangstem Biotech Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-59.95	-28.81	36.12	-28.96	-33.17

Kangstem Biotech Co ROCE % Calculation

Kangstem Biotech Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-6656.922	/	( ( (81253.041 - 24199.159)	+	(55986.114 - 7732.495) )	/ 2 )
	=	-6656.922	/	( (57053.882	+	48253.619)	/ 2 )
	=	-6656.922	/	52653.7505
	=	-12.64 %

Kangstem Biotech Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-16633.784	/	( ( (64127.971 - 12089.368)	+	(55986.114 - 7732.495) )	/ 2 )
	=	-16633.784	/	( ( 52038.603	+	48253.619 )	/ 2 )
	=	-16633.784	/	50146.111
	=	-33.17 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Kangstem Biotech Co (XKRX:217730) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kangstem Biotech Co ROCE % Related Terms

Thank you for viewing the detailed overview of Kangstem Biotech Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kangstem Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kangstem Biotech Co Ltd (XKRX:217730) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 Teheran-ro, Gangnam-gu, 17th Floor, Sinan Building, Seoul, KOR

Website

http://www.kangstem.com

Kangstem Biotech Co Ltd develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

Kangstem Biotech Co Headlines

No Headlines